Cargando…
Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I
Leukocyte adhesion deficiency type I (LAD-I) is a rare autosomal recessive inborn error of immunity (IEI) caused by the defects in CD18, encoded by the ITGB2 gene. LAD-I is characterized by defective leukocyte adhesion to the vascular endothelium and impaired migration of leukocytes. Allogeneic hema...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638093/ https://www.ncbi.nlm.nih.gov/pubmed/36353617 http://dx.doi.org/10.3389/fimmu.2022.1020362 |
_version_ | 1784825331561005056 |
---|---|
author | Yamashita, Motoi Eguchi, Shiori Tomomasa, Dan Kamiya, Takahiro Niizato, Daiki Mitsuiki, Noriko Isoda, Takeshi Funakoshi, Hanako Mizuno, Yuki Okamoto, Kentaro Nguyen, Tuan Minh Takada, Hidetoshi Takagi, Masatoshi Imai, Kohsuke Morio, Tomohiro Kanegane, Hirokazu |
author_facet | Yamashita, Motoi Eguchi, Shiori Tomomasa, Dan Kamiya, Takahiro Niizato, Daiki Mitsuiki, Noriko Isoda, Takeshi Funakoshi, Hanako Mizuno, Yuki Okamoto, Kentaro Nguyen, Tuan Minh Takada, Hidetoshi Takagi, Masatoshi Imai, Kohsuke Morio, Tomohiro Kanegane, Hirokazu |
author_sort | Yamashita, Motoi |
collection | PubMed |
description | Leukocyte adhesion deficiency type I (LAD-I) is a rare autosomal recessive inborn error of immunity (IEI) caused by the defects in CD18, encoded by the ITGB2 gene. LAD-I is characterized by defective leukocyte adhesion to the vascular endothelium and impaired migration of leukocytes. Allogeneic hematopoietic cell transplant (HCT) is the only curative treatment for LAD-I. In an absence of ideal donor for HCT, human leukocyte antigen (HLA)-haploidentical HCT is performed. Posttransplant cyclophosphamide (PT-CY) is a relatively new graft-versus-host disease (GVHD) prophylactic measure and has been increasingly used in HLA-haploidentical HCT for malignant and nonmalignant diseases. However, experience in using PT-CY for rare IEIs, such as LAD-I, is very limited. We report a case of LAD-I successfully treated with HLA-haploidentical HCT with PT-CY. Complete chimerism was achieved, and the patient was cured. Her transplant course was complicated by mild GVHD, cytomegalovirus reactivation and veno-occlusive disease/sinusoidal obstruction syndrome, which were successfully treated. HLA-haploidentical HCT with PT-CY is a safe and effective option for patients with LAD-I when HLA-matched donors are unavailable. |
format | Online Article Text |
id | pubmed-9638093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96380932022-11-08 Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I Yamashita, Motoi Eguchi, Shiori Tomomasa, Dan Kamiya, Takahiro Niizato, Daiki Mitsuiki, Noriko Isoda, Takeshi Funakoshi, Hanako Mizuno, Yuki Okamoto, Kentaro Nguyen, Tuan Minh Takada, Hidetoshi Takagi, Masatoshi Imai, Kohsuke Morio, Tomohiro Kanegane, Hirokazu Front Immunol Immunology Leukocyte adhesion deficiency type I (LAD-I) is a rare autosomal recessive inborn error of immunity (IEI) caused by the defects in CD18, encoded by the ITGB2 gene. LAD-I is characterized by defective leukocyte adhesion to the vascular endothelium and impaired migration of leukocytes. Allogeneic hematopoietic cell transplant (HCT) is the only curative treatment for LAD-I. In an absence of ideal donor for HCT, human leukocyte antigen (HLA)-haploidentical HCT is performed. Posttransplant cyclophosphamide (PT-CY) is a relatively new graft-versus-host disease (GVHD) prophylactic measure and has been increasingly used in HLA-haploidentical HCT for malignant and nonmalignant diseases. However, experience in using PT-CY for rare IEIs, such as LAD-I, is very limited. We report a case of LAD-I successfully treated with HLA-haploidentical HCT with PT-CY. Complete chimerism was achieved, and the patient was cured. Her transplant course was complicated by mild GVHD, cytomegalovirus reactivation and veno-occlusive disease/sinusoidal obstruction syndrome, which were successfully treated. HLA-haploidentical HCT with PT-CY is a safe and effective option for patients with LAD-I when HLA-matched donors are unavailable. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638093/ /pubmed/36353617 http://dx.doi.org/10.3389/fimmu.2022.1020362 Text en Copyright © 2022 Yamashita, Eguchi, Tomomasa, Kamiya, Niizato, Mitsuiki, Isoda, Funakoshi, Mizuno, Okamoto, Nguyen, Takada, Takagi, Imai, Morio and Kanegane https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yamashita, Motoi Eguchi, Shiori Tomomasa, Dan Kamiya, Takahiro Niizato, Daiki Mitsuiki, Noriko Isoda, Takeshi Funakoshi, Hanako Mizuno, Yuki Okamoto, Kentaro Nguyen, Tuan Minh Takada, Hidetoshi Takagi, Masatoshi Imai, Kohsuke Morio, Tomohiro Kanegane, Hirokazu Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title | Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title_full | Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title_fullStr | Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title_full_unstemmed | Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title_short | Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I |
title_sort | case report: hla-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type i |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638093/ https://www.ncbi.nlm.nih.gov/pubmed/36353617 http://dx.doi.org/10.3389/fimmu.2022.1020362 |
work_keys_str_mv | AT yamashitamotoi casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT eguchishiori casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT tomomasadan casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT kamiyatakahiro casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT niizatodaiki casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT mitsuikinoriko casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT isodatakeshi casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT funakoshihanako casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT mizunoyuki casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT okamotokentaro casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT nguyentuanminh casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT takadahidetoshi casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT takagimasatoshi casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT imaikohsuke casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT moriotomohiro casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei AT kaneganehirokazu casereporthlahaploidenticalhematopoieticcelltransplantwithposttransplantcyclophosphamideinapatientwithleukocyteadhesiondeficiencytypei |